M&A

Daichii To Buy U3 for $235M

(BioSpace) Daichii Sankyo bought German based U3 this morning for $235M (150M euro) and I think it’s a pretty good deal for Daichii. U3 is a mAb, receptor tyrosine kinase targeting company with a few candidates in preclinical studies (see below):

Product	Description	Product Type	Status
U3-1287 (AMG-888)	Receptor tyrosine kinase (HER3)	Human antibody	Preclinical
U3-1565	Receptor tyrosine kinase ligand	Human antibody	Preclinical
U3-1800	Receptor tyrosine kinase	Humanized antibody	Preclinical
U3-1784	Receptor tyrosine kinase	Antibody	Research

U3 was started by Professor Axel Ullrich of the Max Planck Institute of Biochemistry, whose pioneering gene technology-based and oncology-focused research led to the development of the oncology blockbusters Herceptin(R) and Sutent(TM).

Can the same man hit gold twice?? I guess Daichii thinks so.

Theoretically Related Posts

• No Related Post

© 2008 Pharmababble.